Advertisement
RMD vs SOLV
Which Stock Would AI Choose? ResMed (RMD) vs. Solventum (SOLV) Stock Comparison
Key Takeaways
- ResMed (RMD) operates in sleep apnea and respiratory care, while Solventum (SOLV) focuses on medical-surgical, dental, and health information systems solutions following its spin-off from 3M.
- Recent market activity shows ResMed (RMD) completing the divestiture of its MatrixCare business, potentially streamlining operations ahead of earnings.
- Solventum (SOLV) faces analyst scrutiny over organic revenue growth and free cash flow margins as it approaches its second-quarter fiscal 2026 results.
- Both stocks operate in the healthcare sector with upcoming earnings reports in early August 2026, providing near-term catalysts for price movement.
- Relative performance reflects broader healthcare sector dynamics, with ResMed (RMD) demonstrating consistent revenue expansion in recent quarters and Solventum (SOLV) navigating post-spin-off adjustments.
- Market sentiment appears mixed for Solventum (SOLV) due to growth concerns, while ResMed (RMD) benefits from established product demand and strategic portfolio adjustments.
Introduction
ResMed (RMD) and Solventum (SOLV) represent distinct segments within the healthcare industry, making them relevant for investors and traders seeking exposure to medical devices, respiratory solutions, and diversified healthcare products. This comparison examines their business models, recent stock behavior, and positioning amid current market conditions. Portfolio managers, sector-focused traders, and long-term investors evaluating relative value in healthcare equities may find this analysis useful for assessing competitive dynamics and potential catalysts in the coming weeks.
ResMed (RMD) Overview and Recent Performance
ResMed (RMD) develops and commercializes medical devices and cloud-based software solutions primarily for sleep-disordered breathing and other respiratory conditions. In recent weeks, the company announced the sale of its MatrixCare business to Frazier Healthcare Partners, a move aimed at refocusing on core respiratory and sleep health operations. This divestiture follows solid third-quarter fiscal 2026 results that included 11% year-over-year revenue growth. Stock performance has reflected steady demand for its flagship products, with sentiment supported by upcoming fourth-quarter earnings scheduled for August 6, 2026. Broader market activity in the medical device space has contributed to relatively stable trading patterns for ResMed (RMD) amid sector rotation.
Solventum (SOLV) Overview and Recent Performance
Solventum (SOLV) provides a range of healthcare solutions across med-surg, dental, and health information systems segments, having been spun off from 3M in 2024. Recent market activity highlights preparations for second-quarter fiscal 2026 earnings on August 5, 2026, with analysts noting challenges including stagnant organic revenue growth and pressure on free cash flow margins. Institutional investors have shown mixed activity in the shares, with some increases in holdings offset by reductions from others. The stock has traded within a defined range near $78, reflecting caution ahead of the earnings release and ongoing adjustments in the post-spin-off environment. Sector sentiment toward diversified healthcare suppliers has influenced recent price behavior.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers across various markets, yet only those demonstrating the strongest alignment with prevailing conditions earn placement in the trending section. Available bots feature diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with many reporting win rates in the 60-80% range and varying profit factors depending on market regimes. This resource allows users to explore automated approaches suited to different risk profiles and market environments. Traders interested in AI-driven strategies can review the full selection on the Trending AI Robots page.
Head-to-Head Comparison
ResMed (RMD) and Solventum (SOLV) differ markedly in business focus: ResMed (RMD) concentrates on specialized respiratory and sleep solutions with recurring software revenue, whereas Solventum (SOLV) offers a broader portfolio spanning wound care, dental products, and health IT systems. Growth drivers for ResMed (RMD) include rising awareness of sleep disorders and product innovation, while Solventum (SOLV) relies on material science applications and cross-selling opportunities post-spin-off. Recent momentum favors ResMed (RMD) due to consistent revenue trends and portfolio streamlining, compared with Solventum (SOLV)’s more variable outlook amid growth concerns. Risk factors for ResMed (RMD) include reimbursement changes in healthcare, while Solventum (SOLV) contends with integration and margin pressures. Both maintain healthcare sector exposure, yet ResMed (RMD) exhibits greater stability in recent market sentiment, whereas Solventum (SOLV) presents potential for re-rating upon earnings clarity.
Tickeron AI Verdict
Based on observable factors such as trend consistency in revenue growth, operational stability following recent divestitures, and relative positioning ahead of earnings, Tickeron’s AI models currently assign a probabilistic preference toward ResMed (RMD). This assessment reflects stronger recent performance metrics and clearer catalysts compared with Solventum (SOLV)’s mixed growth signals. Outcomes remain subject to earnings results and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMD is a Hold and SOLV is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RMD’s FA Score shows that 1 FA rating(s) are green whileSOLV’s FA Score has 1 green FA rating(s).
- RMD’s FA Score: 1 green, 4 red.
- SOLV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RMD’s TA Score shows that 6 TA indicator(s) are bullish while SOLV’s TA Score has 6 bullish TA indicator(s).
- RMD’s TA Score: 6 bullish, 4 bearish.
- SOLV’s TA Score: 6 bullish, 4 bearish.
Price Growth
RMD (@Pharmaceuticals: Other) experienced а +8.05% price change this week, while SOLV (@Pharmaceuticals: Other) price change was +9.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
RMD is expected to report earnings on Aug 06, 2026.
SOLV is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| RMD | SOLV | RMD / SOLV | |
| Capitalization | 30.6B | 14.8B | 207% |
| EBITDA | 2.18B | 2.49B | 88% |
| Gain YTD | -11.945 | 7.824 | -153% |
| P/E Ratio | 20.35 | 10.46 | 195% |
| Revenue | 5.54B | 8.26B | 67% |
| Total Cash | 1.66B | 561M | 296% |
| Total Debt | 843M | 5.29B | 16% |
RMD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 38 | |
PRICE GROWTH RATING 1..100 | 58 | |
P/E GROWTH RATING 1..100 | 84 | |
SEASONALITY SCORE 1..100 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| RMD | SOLV | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 71% | 3 days ago 75% |
| Stochastic ODDS (%) | 3 days ago 66% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 44% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 67% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 72% |
| Advances ODDS (%) | 5 days ago 57% | 5 days ago 65% |
| Declines ODDS (%) | 11 days ago 60% | 3 days ago 59% |
| BollingerBands ODDS (%) | 3 days ago 73% | 3 days ago 61% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 75% |
Advertisement
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with COO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | +1.16% | ||
| COO - RMD | 50% Loosely correlated | -0.45% | ||
| SOLV - RMD | 48% Loosely correlated | -1.59% | ||
| BAX - RMD | 46% Loosely correlated | -2.21% | ||
| BDX - RMD | 45% Loosely correlated | +0.10% | ||
| ISRG - RMD | 43% Loosely correlated | +0.10% | ||
More | ||||